Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007093
Filing Date
2024-05-07
Accepted
2024-05-07 17:16:16
Documents
74
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20240331x10q.htm   iXBRL 10-Q 1633861
2 EX-4.5 crvs-20240331xex4d5.htm EX-4.5 36585
3 EX-10.1 crvs-20240331xex10d1.htm EX-10.1 108583
4 EX-31.1 crvs-20240331xex31d1.htm EX-31.1 11893
5 EX-31.2 crvs-20240331xex31d2.htm EX-31.2 11831
6 EX-32.1 crvs-20240331xex32d1.htm EX-32.1 11803
7 GRAPHIC crvs-20240331x10q006.jpg GRAPHIC 71361
  Complete submission text file 0001558370-24-007093.txt   6821742

Data Files

Seq Description Document Type Size
8 EX-101.SCH crvs-20240331.xsd EX-101.SCH 42583
9 EX-101.CAL crvs-20240331_cal.xml EX-101.CAL 46252
10 EX-101.DEF crvs-20240331_def.xml EX-101.DEF 168817
11 EX-101.LAB crvs-20240331_lab.xml EX-101.LAB 378931
12 EX-101.PRE crvs-20240331_pre.xml EX-101.PRE 296622
78 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20240331x10q_htm.xml XML 986781
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 24923237
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)